New Jersey is currently home to 1720 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Functional Oral-Pharyngeal Rehabilitation of Patients With Dysphagia Using Ice-chips, a Prospective Randomized Study
Recruiting
The objective of this study is to evaluate the effectiveness of early swallowing intervention in post extubated patients in the ICU to determine if this minimizes the risk of aspiration, increases initiating of oral intake sooner, reduced length of ICU stay and reduces the need for alternate means of nutrition/hydration. Patients will be randomly assigned to either Group A or B. We will decide grouping, using wheel that will randomly select group A or B after spinning. All participants will re... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
08/12/2022
Locations: Morristown Medical Center, Morristown, New Jersey
Conditions: Post Extubation Dysphagia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The Leaflex™ Early Feasibility Study
Recruiting
A prospective, multicenter, single-arm, early feasibility study aimed to assess safety and performance of the Leaflex™ Performer in the treatment of patients with symptomatic, severe aortic stenosis. Subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12 months post procedure.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: Atlantic Health System Hospital Corp - Morristown Medical Center, Morristown, New Jersey
Conditions: Aortic Valve Stenosis
A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan
Recruiting
The overall goal of this study is to explore the effectiveness of using acupuncture versus aromatherapy, in conjunction with standard of care anti-emetics, to decrease chemotherapy induced nausea, vomiting, and anxiety in breast cancer patients undergoing Adriamycin and Cytoxan. This study also aims to determine if aromatherapy and anti-emetics is more effective than acupuncture and anti-emetics in treating nausea, vomiting, and anxiety in patients receiving Adriamycin and Cytoxan and if acupunc... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/25/2022
Locations: Englewood Health, Englewood, New Jersey
Conditions: Nausea, Vomiting, Anxiety
Afferent Neurocardiac Signals, Cue Reactivity, and Cognitive Control
Recruiting
Conscious attempts to regulate alcohol use are often undermined by automatic attention and arousal processes activated by alcohol cues, as well as by diminished ability to inhibit in-the-moment behaviors. The current study will examine whether a brief behavioral intervention of slow breathing paced at a resonance frequency of the cardiovascular system can interrupt automatic alcohol cue reactivity and enhance cognitive control in binge drinkers. Results from the proposed study may provide new pr... Read More
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
07/15/2022
Locations: Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Conditions: Binge Drinking
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: Premier Urology Group, Edison, New Jersey
Conditions: Hypogonadism
Evaluation of the FELLAS Responsible Fatherhood Project
Recruiting
The Partnership for Maternal and Child Health of Northern New Jersey, Inc. (PMCH) is implementing a fatherhood project with the goal of strengthening father-child engagement, improving economic stability, and improving healthy marriage/relationship skills among participants. FELLAS serves community-based fathers 18 years of age or older who reside in Essex County, New Jersey and have at least one child under the age of 24. The program model has three components: to improve responsible parenting... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/07/2022
Locations: Partnership for Maternal & Child Health of Northern New Jersey, Newark, New Jersey
Conditions: Responsible Fatherhood
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Cooper University Hospital, Camden, New Jersey
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Cross-sectional Evaluation of the Subjective Performance and Satisfaction With Ponto Sound Processors
Recruiting
The study is a non-interventional, observational, cross-sectional, study on users of Ponto sound processors. The purpose of this study is to evaluate subjectively assessed hearing performance and satisfaction with Oticon Medical's sound processors fitted with the Genie Medical fitting software.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2022
Locations: Oticon Medical, Somerset, New Jersey
Conditions: Hearing Loss, Hearing Loss, Conductive, Hearing Loss, Unilateral
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
Recruiting
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2022
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Relapsed/Refractory Multiple Myeloma
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
Recruiting
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/09/2022
Locations: Hassman Research Institute, Berlin, New Jersey
Conditions: Vasomotor Symptoms, Menopausal Symptoms
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Recruiting
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: Columbia University Medical Center, Fort Lee, New Jersey
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis